HLX-3902

N/A

Report date: 2026/05/25 20:02:40

Base Information

Drug NameHLX-3902

Drug Alias NameHLX-3902

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > T cell engagers

Mechanisms of ActionAnti-STEAP1CD3 T-cell engagersAnti-CD28

TargetsSix-transmembrane epithelial antigen of the prostate 1T cell surface glycoprotein CD3T-cell-specific surface glycoprotein CD28

Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaIND

Originator CompaniesShanghai Henlius Biotech Inc

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Henlius Biotech Inc

Inactive CompaniesN/A

Active IndicationsSolid tumoursNeoplasm MetastasisProstatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A